Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramosetron vs Loperamide for Low Anterior Resection Syndrome
NCT05577845Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial of ramosetron in low anterior resection syndrome (LARS) (2 arms), sponsored by Seoul National University Hospital. Primary endpoints: Major Low Anterior Resection Syndrome Score at 4 weeks and Difference of improvement of major Low Anterior Resection Syndrome at 4 weeks. Started Mar 2023; status: recruiting.
02
Drugs
ramosetron
03
Conditions
low anterior resection syndrome (LARS)
Beyond the preview
Go deeper on NCT05577845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577845.